Paliperidone extended-release for the treatment of schizophrenia. - Wikidata - wikimedia - TriplyDB

Paliperidone extended-release for the treatment of schizophrenia.

Paliperidone extended-release for the treatment of schizophrenia.

http://www.wikidata.org/entity/Q37281593

about

Oral paliperidone for schizophrenia Paliperidone for the treatment of ketamine-induced psychosis: a case report.Paliperidone: a review of clinical trial data and clinical implications.Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability.Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia.Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines.A review of paliperidone palmitate.The pharmacology and formulation of paliperidone extended release.Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.Clinically significant drug interactions with atypical antipsychotics.White-matter connectivity related to paliperidone treatment response in patients with schizophrenia.Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.Treatment of bipolar mania with paliperidone extended-release.Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study.Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers.Effects of paliperidone palmitate on coagulation: an experimental study.Social interaction and drug attitude effectiveness in patients with schizophrenia.

P2860

Q24242948-3506B7B0-41B3-4D53-B8C4-58E932504D97 Q30368451-2C282DE5-14E8-4E59-A391-E105FF948DAF Q34321924-05C0450C-DB84-4C38-B855-7620667FFFC5 Q35151598-4B9024F2-6170-436F-AEF7-99E2D9DF0C54 Q36873906-3AD6C8B3-FAAB-4D07-B5E3-1DE65A82A4F0 Q37794336-C93E5A07-8B3B-41B3-8706-ACE20402B9D5 Q38067137-3CFF0FC4-1E74-48DD-B635-9D332810580B Q38067139-DFCAA5FB-399A-4CFC-A05D-A46E356F6583 Q38099224-5B3F4802-A8CD-4D09-BCA8-7BE6C9B27898 Q38156416-0F9BCCC9-AD68-4FAD-B7F4-D0D83B8BE9A7 Q40119382-DC4BE733-BB20-4F3D-8E02-CF231C8CB6FE Q42658342-193EA208-3E9D-4741-A062-8685D18C2794 Q45774230-9703938C-801D-4EDF-9B04-2B411E2B655B Q48004326-9C5D38FA-B87D-4166-B069-BC3D78BDE2E7 Q50757787-29D85FD5-6953-4EEF-933B-6BAA4D1AD989 Q51143654-9A8316BF-DA8E-451C-AA63-A21AC247AAED Q51578149-C287FADE-5F59-4E23-BDBC-078AE179D2D2

P2860

Paliperidone extended-release for the treatment of schizophrenia.

http://www.wikidata.org/entity/Q37281593

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Paliperidone extended-release for the treatment of schizophrenia.

@en

Paliperidone extended-release for the treatment of schizophrenia.

@nl

type

label

Paliperidone extended-release for the treatment of schizophrenia.

@en

Paliperidone extended-release for the treatment of schizophrenia.

@nl

prefLabel

Paliperidone extended-release for the treatment of schizophrenia.

@en

Paliperidone extended-release for the treatment of schizophrenia.

@nl

P1433

Q37281593-09A433A5-4F84-40BB-9748-37415188BEE0

P1476

Q37281593-DDAD77F3-22CB-4A48-AA82-30E91E217B1E

P2093

Q37281593-90E86C81-8444-4BEF-B5F6-71585B803466

Q37281593-A6584F39-A748-4EF9-92DF-720ECDB9C9E9

P2860

Q37281593-09C26C35-2363-4B89-8FCE-E133F32772C0

Q37281593-11131E3B-932C-4BD2-BBEE-330600744685

Q37281593-368D455A-6CDF-4556-9806-8801D9D097AC

Q37281593-39F7CB2D-DB53-463B-9A3E-1EA393F9BDE3

Q37281593-3BA8B42C-51DD-46BD-8C44-C4F39D212B30

Q37281593-3E9A7D02-23E7-4FCC-BB88-B791811D2F9D

Q37281593-428CF3A5-AD41-4917-BDAC-9B068686F78C

Q37281593-4C4C96F7-E396-4E62-A3D0-D348A818B3D3

Q37281593-51E857D8-F034-411E-A5A1-B8C714EA1085

Q37281593-606B0651-9837-4145-9C8C-44B24FF25CA2

P304

Q37281593-1CECACB0-BAE3-4A15-BAD4-03E2A6885714

P31

Q37281593-EAD99365-4C33-420C-A5B5-A4062B140092

Q37281593-b65ceda1-053f-4e09-bf92-e02a6ea0b1de

P356

Q37281593-2718EB02-E03B-4CFF-ACB0-451AD4E19F5C

P407

Q37281593-4B1CB0E1-8E29-495D-9CD5-AEC094EA8476

P433

Q37281593-A9571154-D64D-4EDD-8CD7-5EEB112A8B42

P478

Q37281593-A9DD03E3-DACA-42F6-9717-729DFB8C9E02

P577

Q37281593-9C4FBF7D-1D2D-469E-8454-8064B9888F6B

P698

Q37281593-11C8583A-DC39-4868-BC26-D47FAA86C5CA

P921

Q37281593-BCDB00D7-B59B-4E72-BC3C-FD4C8B56AC7B

P356

PHCO.28.10.1283

P1433

Pharmacotherapy

P1476

Paliperidone extended-release for the treatment of schizophrenia.

@en

P2093

Jehan Marino

http://www.w3.org/2001/XMLSchema#string

Joshua Caballero

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.

Survey on the pharmacodynamics of the new antipsychotic risperidone.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

P304

1283-1298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.28.10.1283

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18823223

http://www.w3.org/2001/XMLSchema#string

P921